Marshall Wace LLP Sells 67,509 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Marshall Wace LLP decreased its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 33.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 133,191 shares of the company's stock after selling 67,509 shares during the quarter. Marshall Wace LLP owned 0.36% of Lifecore Biomedical worth $990,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Barclays PLC increased its stake in Lifecore Biomedical by 13.5% during the fourth quarter. Barclays PLC now owns 33,972 shares of the company's stock valued at $253,000 after acquiring an additional 4,028 shares during the period. Invesco Ltd. acquired a new position in shares of Lifecore Biomedical in the fourth quarter valued at $4,128,000. Wells Fargo & Company MN lifted its position in Lifecore Biomedical by 29.0% in the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after purchasing an additional 3,012 shares during the period. Rangeley Capital LLC acquired a new stake in Lifecore Biomedical during the fourth quarter worth $325,000. Finally, Geode Capital Management LLC increased its holdings in Lifecore Biomedical by 14.7% in the 4th quarter. Geode Capital Management LLC now owns 685,746 shares of the company's stock valued at $5,097,000 after buying an additional 88,061 shares during the period. Institutional investors and hedge funds own 83.36% of the company's stock.

Lifecore Biomedical Price Performance

Shares of LFCR stock traded down $0.08 during trading hours on Tuesday, hitting $6.94. The company had a trading volume of 26,617 shares, compared to its average volume of 240,558. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $7.99. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The firm's fifty day moving average is $6.32 and its 200 day moving average is $6.46. The firm has a market capitalization of $256.95 million, a price-to-earnings ratio of -12.39 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $35.15 million during the quarter, compared to the consensus estimate of $33.23 million. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, sell-side analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.